Angiotensin receptor blocker therapy for heart failure patients: Is combination treatment a feasible prospect?

Clinical Cardiology

Volumn 32, Issue 9, 2009, Pages 513-518

  Mehta, P A ^a   McDonagh, S ^b   Phillips, J ^b   Grocott Mason, R ^b   Dubrey, S W ^b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b HILLINGDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANDESARTAN; ENALAPRIL; LISINOPRIL; PERINDOPRIL; RAMIPRIL;

AGED; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENERAL HOSPITAL; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; OPTIMAL DRUG DOSE; PATIENT SATISFACTION; PATIENT SELECTION; RECOMMENDED DRUG DOSE;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; DRUG THERAPY, COMBINATION; FEASIBILITY STUDIES; FEMALE; HEART FAILURE; HOSPITALS, DISTRICT; HOSPITALS, GENERAL; HUMANS; HYPERKALEMIA; LONDON; MALE; MIDDLE AGED; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; STROKE VOLUME; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 70349490796     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20635     Document Type: Article

References (28)

1. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26(11):1115-1140.
2. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult-Summary Article A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005;46(6):1116-1143.
3. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429-1435.
4. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821-828. (Pubitemid 23285909)
5. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327(10):669-677.
6. TRACE Study Group. A clinical trial of angiotensin converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. The Trandolapril Cardiac Evaluation (TRACE) Study. N Engl J Med. 1995;333:1670-1676.
7. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353: 2001-2007. (Pubitemid 29271744)
8. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309-1321. (Pubitemid 36384098)
9. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709-717.
10. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293-302.
11. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9-13.
12. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996; 334(21):1349-1355.
13. Cowie MR, Wood DA, Coats AJ, et al. Survival of patients with a new diagnosis of heart failure: a population based study. Heart. 2000;83(5):505-510.
14. Cowie MR, Fox KF, Wood DA, et al. Hospitalization of patients with heart failure: a population-based study. Eur Heart J. 2002; 23(11):877-885. (Pubitemid 34717423)
15. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 1993;88(1):107-115. (Pubitemid 23195439)
16. Baruch L, Anand I, Cohen IS, Ziesche S, Judd D, Cohn JN. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group. Circulation. 1999;99(20):2658-2664. (Pubitemid 29237453)
17. McKelvie RS, Rouleau JL, White M, et al. Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure. Eur Heart J. 2003;24(19):1727-1734. (Pubitemid 37236861)
18. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2001;22(17): 1527-1560. (Pubitemid 32801300)
19. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America. Circulation. 2001;104(24):2996-3007.
20. McMurray J, Cohen-Solal A, Dietz R, et al. Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice. Eur J Heart Fail. 2001;3(4):495-502. (Pubitemid 32780528)
21. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362(9386):767-771. (Pubitemid 37093916)
22. Sahn DJ, DeMaria A, Kisslo J, Weyman A. The Committee on M-mode standardization of the American Society of Echocardiography. Recommendations regarding quantitation in M-mode echocardiographicmeasurements. Circulation. 1978;58:1072-1082.
23. Henry WL, DeMaria A, Gramiak R, et al. Report of the American Society of Echocardiography Committee on Nomenclature and Standards in Two-dimensional Echocardiography. Circulation. 1980;62(2):212-217. (Pubitemid 10035638)
24. Swedberg K, Granger C, Held P, et al. Candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. J Card Fail. 1999;5(3):276-282. (Pubitemid 29449267)
25. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29(19): 2388-2442.
26. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20): 1893-1906. (Pubitemid 37409706)
27. Cowie MR, Wood DA, Coats AJ, et al. Incidence and aetiology of heart failure; a population-based study. Eur Heart J. 1999;20(6): 421-428. (Pubitemid 29116538)
28. Mehta PA, Dubrey SW, McIntyre HF, et al. Mode of death in patients with newly diagnosed heart failure in the general population. Eur J Heart Fail. 2008;10(11):1108-1116.